HROW – harrow health, inc. (US:NASDAQ)

News

Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com